

Christopher K Finch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8301756/publications.pdf>

Version: 2024-02-01

56
papers

1,531
citations

516215

16
h-index

315357

38
g-index

57
all docs

57
docs citations

57
times ranked

2096
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical and economic burden of chronic obstructive pulmonary disease in the USA. ClinicoEconomics and Outcomes Research, 2013, 5, 235.	0.7	262
2	Rifampin and Rifabutin Drug Interactions. Archives of Internal Medicine, 2002, 162, 985.	4.3	209
3	Update on rifampin, rifabutin, and rifapentine drug interactions. Current Medical Research and Opinion, 2013, 29, 1-12.	0.9	138
4	Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2008, 99, 208-214.	1.8	137
5	Update on Rifampin and Rifabutin Drug Interactions. American Journal of the Medical Sciences, 2008, 335, 126-136.	0.4	128
6	A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. Journal of Neuro-Oncology, 2010, 99, 251-260.	1.4	67
7	Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 421.	0.9	61
8	Possible Gatifloxacin-Induced Hyperglycemia. Annals of Pharmacotherapy, 2004, 38, 602-605.	0.9	34
9	Early vs Delayed Enteral Nutrition in Critically Ill Medical Patients. Nutrition in Clinical Practice, 2010, 25, 205-211.	1.1	33
10	Evaluation of glycemic control following discontinuation of an intensive insulin protocol. Journal of Hospital Medicine, 2009, 4, 28-34.	0.7	32
11	Treatment of Lithium-Induced Diabetes Insipidus with Amiloride. Pharmacotherapy, 2003, 23, 546-550.	1.2	27
12	Acute Inhalant-Induced Neurotoxicity with Delayed Recovery. Annals of Pharmacotherapy, 2005, 39, 169-172.	0.9	25
13	Anticonvulsant Hypersensitivity Syndrome: Treatment with Corticosteroids and Intravenous Immunoglobulin. Southern Medical Journal, 2004, 97, 319-321.	0.3	23
14	Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. American Journal of Geriatric Pharmacotherapy, 2008, 6, 33-36.	3.0	22
15	An Evaluation of Peak Expiratory Flow Monitoring: A Comparison of Sitting Versus Standing Measurements. Journal of the American Board of Family Medicine, 2010, 23, 166-170.	0.8	21
16	Blood pressure management in acute hypertensive emergency. American Journal of Health-System Pharmacy, 2007, 64, 2579-2582.	0.5	17
17	Potential Role of Leukotriene Modifiers in the Treatment of Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2008, 28, 1183-1187.	1.2	17
18	Lower Serum Digoxin Concentrations in Heart Failure and Reassessment of Laboratory Report Forms. American Journal of the Medical Sciences, 2002, 324, 10-13.	0.4	14

#	ARTICLE	IF	CITATIONS
19	Use of fibrin glue to treat a persistent pneumothorax with bronchopleural fistula. American Journal of Health-System Pharmacy, 2008, 65, 322-324.	0.5	14
20	Inhaler Use in Hospitalized Patients with Chronic Obstructive Pulmonary Disease or Asthma: Assessment of Wasted Doses. Hospital Pharmacy, 2015, 50, 386-390.	0.4	14
21	Pharmacist Transition-of-Care Services Improve Patient Satisfaction and Decrease Hospital Readmissions. Journal of Pharmacy Practice, 2022, 35, 86-93.	0.5	14
22	Heparin-induced thrombocytopenia complicated by warfarin-induced skin necrosis. American Journal of Health-System Pharmacy, 2008, 65, 1144-1147.	0.5	13
23	Gabapentin Withdrawal Syndrome in a Post-Liver Transplant Patient. Journal of Pain and Palliative Care Pharmacotherapy, 2010, 24, 236-238.	0.5	13
24	Peak Expiratory Flow in Bed? A Comparison of 3 Positions. Respiratory Care, 2013, 58, 494-497.	0.8	13
25	Evaluation of the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. American Journal of the Medical Sciences, 2015, 349, 36-41.	0.4	13
26	Nicotine Replacement Therapy-associated Syndrome of Inappropriate Antidiuretic Hormone. Southern Medical Journal, 2004, 97, 322-324.	0.3	13
27	Gender Differences in the Use of Peak Flow Meters and Their Effect on Peak Expiratory Flow. Pharmacotherapy, 2005, 25, 526-530.	1.2	12
28	Are we failing to document adequate smoking histories? A brief review 1999-2009. Current Medical Research and Opinion, 2010, 26, 1691-1696.	0.9	12
29	ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2021, 78, 472-497.	0.5	12
30	End-Stage Renal Disease Increases Rates of Adverse Glucose Events When Treating Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic State. Clinical Diabetes, 2017, 35, 202-208.	1.2	11
31	Incorrect use of peak flow meters: are you observing your patients?. Journal of Asthma, 2014, 51, 566-572.	0.9	10
32	Development and application of quality measures of clinical pharmacist services provided in inpatient/acute care settings. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1601-1617.	0.5	10
33	Hyperkalemia-Induced Paralysis. Pharmacotherapy, 2009, 29, 1270-1272.	1.2	9
34	Early Versus Delayed Initiation of Pharmacological Venous Thromboembolism Prophylaxis After an Intracranial Hemorrhage. Neurologist, 2017, 22, 166-170.	0.4	9
35	Inadequate Documentation of Asthma Management in Hospitalized Adult Patients. Southern Medical Journal, 2009, 102, 510-514.	0.3	8
36	Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?. Respiratory Medicine, 2016, 119, 135-140.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia. American Journal of the Medical Sciences, 2020, 360, 35-41.	0.4	8
38	Impact of a Pharmacist-Driven Poststroke Transitions of Care Clinic on 30 and 90-Day Hospital Readmission Rates. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104648.	0.7	8
39	Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease. Current Medical Research and Opinion, 2021, 37, 1581-1588.	0.9	8
40	Overuse of Antihypertensives in Patients with Acute Ischemic Stroke. Southern Medical Journal, 2006, 99, 1230-1233.	0.3	8
41	Management and treatment of lithium-induced nephrogenic diabetes insipidus. Therapy: Open Access in Clinical Medicine, 2005, 2, 669-675.	0.2	4
42	Aripiprazole-Induced Diabetic Ketoacidosis: Remaining Vigilant. Hospital Pharmacy, 2011, 46, 432-435.	0.4	4
43	An Evaluation of Inhaled Bronchodilator Therapy in Patients Hospitalized for Non-Life-Threatening COPD Exacerbations. Southern Medical Journal, 2011, 104, 742-745.	0.3	3
44	Action plans to reduce hospitalizations for chronic obstructive pulmonary disease exacerbations: focus on oral corticosteroids. Current Medical Research and Opinion, 2014, 30, 2607-2615.	0.9	3
45	GENDER DIFFERENCES IN PEAK FLOW METER USE. Nurse Practitioner, 2007, 32, 46-48.	0.2	2
46	Severe Ceftaroline-Induced Thrombocytopenia With Rapid Onset on Rechallenge. Annals of Pharmacotherapy, 2020, 54, 187-188.	0.9	2
47	The Hunger for Mirtazapine: A Discontinuation Syndrome. Journal of Pain and Palliative Care Pharmacotherapy, 2021, 35, 113-116.	0.5	2
48	INADEQUATE DOCUMENTATION OF SMOKING HISTORY IN HOSPITALIZED PATIENTS FOR ASTHMA WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (ICD-9 CODE 493.2). Chest, 2009, 136, 119S.	0.4	1
49	Pharmacist-Managed Direct Thrombin Inhibitor Protocol Improves Care of Patients with Heparin-Induced Thrombocytopenia. Hospital Pharmacy, 2010, 45, 705-711.	0.4	1
50	Management and treatment of lithium-induced nephrogenic diabetes insipidus. Therapy: Open Access in Clinical Medicine, 2005, 2, 669-675.	0.2	1
51	An Evaluation of the Management of Non-Life-Threatening COPD Exacerbations in Hospitalized Patients. Chest, 2010, 138, 475A.	0.4	0
52	An Evaluation of Inhaled Bronchodilator Therapy in Patients Hospitalized for Non-Life-Threatening COPD Exacerbations. Chest, 2010, 138, 712A.	0.4	0
53	Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. PLoS ONE, 2017, 12, e0188390.	1.1	0
54	“And Now a Word from Our Sponsor” Big Pharma. Southern Medical Journal, 2008, 101, 340-341.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Fluconazole-carbamazepine interaction. Southern Medical Journal, 2002, 95, 1099-100.	0.3	0
56	Evaluation of Hospitalized Patients Receiving High versus Low-Dose Opioids for Non-Cancer Pain. Journal of Pain and Palliative Care Pharmacotherapy, 0, , 1-8.	0.5	0